

Status: Currently Official on 17-Feb-2025
Official Date: Official as of 01-Aug-2023
Document Type: USP Monographs
DocId: GUID-822DADEE-0A00-44BF-A975-D7109FCD22D9_2_en-US
DOI: https://doi.org/10.31003/USPNF_M12438_02_01
DOI Ref: 7b11p

© 2025 USPC
Do not distribute

Add the following:

Valine Compounded Oral Solution

DEFINITION

Valine Compounded Oral Solution contains NLT 90.0% and NMT 110.0% of the labeled amount of valine (C₅H₁₁NO₂).

Prepare Valine Compounded Oral Solution 10 mg/mL as follows (see [Pharmaceutical Compounding—Nonsterile Preparations \(795\)](#)).

Valine	1 g
Methylparaben	0.05 g
Propylparaben	0.025 g
Purified Water, a sufficient quantity to make	100 mL

In an appropriately sized container, add *Methylparaben* and *Propylparaben* to about 80 mL of *Purified Water*. Stir until dissolved. [NOTE—May heat up to 50° to facilitate dissolution.] Dissolve the *Valine* in the previously prepared solution of *Methylparaben* and *Propylparaben* and bring to final volume with *Purified Water*.

ASSAY

PROCEDURE

- Solution A:** 6.8 g/L of potassium phosphate monobasic in water. Filter.
- Mobile phase:** Acetonitrile and *Solution A* (65:35). Filter.
- Diluent:** Acetonitrile and *Solution A* (50:50)
- Standard solution:** 1 mg/mL of [USP L-Valine RS](#) in *Diluent*
- Sample solution:** Transfer 1 mL of Oral Solution into a 10-mL volumetric flask, dilute with *Diluent* to volume, and mix.
- Chromatographic system**
(See [Chromatography \(621\)](#), [System Suitability](#).)
- Mode:** LC
- Detector:** UV 210 nm
- Column:** 4.6-mm × 25-cm; 5-μm packing [L8](#)
- Flow rate:** 1.0 mL/min
- Injection volume:** 10 μL
- System suitability**
- Sample:** *Standard solution*
- [NOTE—The retention time for valine is about 8.9 min.]
- Suitability requirements**
- Tailing factor:** NMT 2.0
- Relative standard deviation:** NMT 2.0% for replicate injections

Analysis

- Samples:** *Standard solution* and *Sample solution*
- Calculate the percentage of the labeled amount of valine (C₅H₁₁NO₂) in the portion of Oral Solution taken:

Result = (r_U/r_S) × (C_S/C_U) × 100

r_U = peak response of valine from the *Sample solution*

r_S = peak response of valine from the *Standard solution*

C_s = concentration of [USP L-Valine RS](#) in the *Standard solution* (mg/mL)

C_u = nominal concentration of valine in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

SPECIFIC TESTS

- [pH \(791\)](#): 5.7–6.7

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Package in tight, light-resistant containers. Store in a refrigerator or at controlled room temperature.
- **BEYOND-USE DATE:** NMT 90 days after the date on which it was compounded when stored in a refrigerator or at controlled room temperature
- **LABELING:** Label it to state the *Beyond-Use Date*.
- [USP REFERENCE STANDARDS \(11\)](#)
[USP L-Valine RS](#) ▲ (USP 1-Aug-2023)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
VALINE COMPOUNDED ORAL SOLUTION	Brian Serumaga Science Program Manager	CMP2020 Compounding 2020
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	CMP2020 Compounding 2020

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 46(3)

Current DocID: [GUID-822DADEE-0A00-44BF-A975-D7109FCD22D9_2_en-US](#)

DOI: https://doi.org/10.31003/USPNF_M12438_02_01

DOI ref: [7b11p](#)